Michael Friedman, MD, Board Director of Cytovia Therapeutics, discusses the transformation that cellular therapy and NK cells represent in cancer treatment, how iPSC NK technology is promising to provide access to treatment to more cancer patients, and Cytovia's potential as an emerging biotech company. Michael was previously CEO of City of Hope Cancer Center, Acting Commissioner of the FDA, and Board Member at Celgene.

Justin Eyquem, PhD, Parker Fellow at the University of California San Francisco , discusses the advances in Natural Killer cells derived from induced pluripotent stem cells (iPSCs) and the potential of gene-editing to design precision cell therapeutics. Dr. Eyquem is conducting research sponsored by Cytovia Therapeutics aiming to optimize the design of chimeric antigen receptors (CAR) and the selection of CAR insertion loci.

Laurent Audoly, PhD and Leila Alland, MD, Board Directors at Cytovia Therapeutics, discuss the transformation that cellular therapy and NK cells represent in cancer treatment, how iPSC NK technology is promising to provide access to treatment to more cancer patients, and Cytovia's potential as an emerging biotech company. Laurent is the co-founder of Cytovia Therapeutics, was co-founder and CEO at Kymera Therapeutics, and previously held leadership positions at Pfizer, Merck, and Pieris. Leila Alland is the Chief Medical Officer at PMV Pharmaceuticals, was formerly Chief Medical Officer at Affimed, and previously held leadership positions at AstraZeneca, Bristol-Myers Squibb, and Novartis.